Brussels (Belgium) 27th August 2010 – DNAVision, Europe’s leading genetic analysis
service providers, is pleased to announce the acquisition beginning of August of an
additional Illumina HiSeq 2000 sequencing platform. The new system will be ready for
service to customer early October, just a few months after the first HiSeq system has
successfully entered into operation. Due to the high cost-effectiveness and sequencing
output, DNAVision uses the HiSeq 2000 systems mainly for human genome sequencing.

About DNAVision

Brussels (Belgium) 17th May 2010 – DNAVision, one of Europe’s leading genetic analysis service providers, is pleased to announce the purchase of Illumina’s new HiScanSQ™ microarray and next-generation sequencing platform, which has officially been launched one month ago.

Illumina’s latest system will be installed in Gosselies’ facility and implemented in the highest quality certified environment (GMP, GLP, CLIA, CAP, ISO17025).

TARZANA, Calif., April 16, 2010 --- Today, EntroGen announced that it has entered into a collaboration and licensing agreement with the Childrens Hospital Los Angeles to develop a molecular diagnostic test for Ewing’s Sarcoma Family of tumors (EFT). The test will be based on a highly specific biomarker discovered at CHLA/USC and will offer oncologists a definitive diagnosis of EFT.

Chemotherapy generally improves survival in postmenopausal breast cancer patients, according to a landmark study led by Dr. Kathy Albain of Loyola University Health System.

Eighteen single-point genetic variations indicate risk of recurrence for early-stage head and neck cancer patients and their likelihood of developing a second type of cancer, researchers at The University of Texas M. D. Anderson Cancer Center reported at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

Long-chain omega-3 fatty acids, primarily found in fish and seafood, may have a role in colorectal cancer prevention, according to results presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9, 2009, in Houston.

Belgian Embassy in Beijing, November 23th 2009 – DNAVision one of the European leading genetic analysis service provider, and the Beijing Genomics Institute-Hong Kong (BGI-HK, a spin-off of Beijing Genome Institute at Shenzhen, which is the third biggest genome centre in the world) announced today that they have entered into a strategic alliance to increase its position in Next Generation sequencing field.

Liege, 20th November – DNAVision, a European-based genomic service provider, announced today that it has successfully completed Illumina CSPro™ certification for Infinium Genotyping, gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.

Women with increased levels of Müllerian inhibiting substance (MIS), best known for regulating in utero sexual differentiation in boys, may be at a greater risk for breast cancer, according to a new study published online October 9 in the .

According to a new study published in the October issue of the Journal of the American College of Surgeons, although breast-conserving surgery (BCS), commonly known as lumpectomy, is increasingly being used to treat older women with nonmetastatic invasive breast cancer, there are still significant socioeconomic and geographic disparities in the use of this type of therapy. For example, women in the Northeast and Pacific West are significantly more likely to receive BCS than those in the South and parts of the Midwest.